CN102920684B - Tetradotoxin mask and preparation method thereof - Google Patents
Tetradotoxin mask and preparation method thereof Download PDFInfo
- Publication number
- CN102920684B CN102920684B CN201210459177.9A CN201210459177A CN102920684B CN 102920684 B CN102920684 B CN 102920684B CN 201210459177 A CN201210459177 A CN 201210459177A CN 102920684 B CN102920684 B CN 102920684B
- Authority
- CN
- China
- Prior art keywords
- fugu ocellatus
- ocellatus toxin
- pad pasting
- tetradotoxin
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 title abstract description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 239000008101 lactose Substances 0.000 claims abstract description 8
- 229940099259 vaseline Drugs 0.000 claims abstract description 8
- 239000011787 zinc oxide Substances 0.000 claims abstract description 8
- 239000003381 stabilizer Substances 0.000 claims abstract description 3
- 241000054452 Takifugu ocellatus Species 0.000 claims description 99
- 239000003053 toxin Substances 0.000 claims description 99
- 231100000765 toxin Toxicity 0.000 claims description 99
- 239000003814 drug Substances 0.000 claims description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 9
- 229940075930 picrate Drugs 0.000 claims description 9
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001640 fractional crystallisation Methods 0.000 claims description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 208000002193 Pain Diseases 0.000 abstract description 16
- 208000003251 Pruritus Diseases 0.000 abstract description 15
- 230000036407 pain Effects 0.000 abstract description 15
- 238000002347 injection Methods 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000007803 itching Effects 0.000 abstract description 4
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 238000010606 normalization Methods 0.000 abstract description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 abstract 1
- 239000000341 volatile oil Substances 0.000 abstract 1
- 230000037303 wrinkles Effects 0.000 description 19
- 230000003796 beauty Effects 0.000 description 15
- 239000011505 plaster Substances 0.000 description 12
- 230000036592 analgesia Effects 0.000 description 8
- 230000001139 anti-pruritic effect Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 239000003908 antipruritic agent Substances 0.000 description 6
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 6
- 229950010357 tetrodotoxin Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 108030001720 Bontoxilysin Proteins 0.000 description 4
- 208000018526 Narcotic-Related disease Diseases 0.000 description 4
- 229940053031 botulinum toxin Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 201000005040 opiate dependence Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a tetradotoxin mask and a preparation method of the mask. The tetradotoxin mask comprises an active pharmaceutical ingredient tetradotoxin, stabilizer lactose, a complex solubilizer citric acid, zinc oxide, rosin, vaseline and mint essential oil and the like. Based on different amounts of tetradotoxin contained in the mask, the mask has the effects of relieving itching, easing pain and lifting face. The tetradotoxin mask changes the traditional administration manner of tetradotoxin, and is more convenient to use. The tetradotoxin mask is low in price, simple and easy to manufacture, fast in effect, long in lasting time, healthy and clean. In addition, the mask further conquers the social safety hazard caused by the original tetradotoxin injection is missed, and facilitates promoting normalization of the face lifting item. The consumer can quickly, conveniently and comfortably care the skins without beautifying medical institutions.
Description
Technical field
The present invention relates to a kind of Fugu ocellatus toxin external used medicine, relate in particular to a kind of Fugu ocellatus toxin pad pasting.
Background technology
Fugu ocellatus toxin (Tetrodotoxin is called for short TTX), is a kind of micromolecule amount, non-protein compound, its molecular formula: C
11h
17n
3o
8, molecular weight is 319.27.Fugu ocellatus toxin has local irritant effect to intestinal, after entering and being absorbed in organism, act on teleneuron and nerve centre by blood circulation, can high selectivity, Voltage-gated Sodium Channels on high-affinity ground blocking-up neural excitation film, thereby retardance organism current potential, suppresses excited conduction between neuromuscular, finally causes associated physiological function obstacle, main manifestations is muscle and neural paralysis, can play the effects such as analgesia, anesthesia, treating narcotic addiction.The clinical fields such as internal medicine, surgery, department of dermatologry that are mainly used in.Its function mainly contains the following aspects: 1, analgesia, be used to containing the injection of Fugu ocellatus toxin the pain that neuralgia, cancer pain, arthralgia, myalgia, leprosy pain and wound, contusion, burn cause, and especially remarkable to tetanic spasm effect; 2, local anesthesia, because the anesthetic action of Fugu ocellatus toxin is than ten thousand times eager to excel in whatever one does of general local anesthetic, outside native land, existing Fugu ocellatus toxin is joined the patent sale as anesthetics with general anesthesia recurrence due to taking drug; 3, calmness, can make pruritus tranquilizer, and skin pruritus, dermatitis etc. are had to itching-relieving efficacies, and has curative effect, also can be used as resiratoryp sedative, the symptoms such as treatment asthma, pertussis; 4, blood pressure lowering, tetrodotoxin, TTX have unique blood pressure lowering effect, can be clinically for rescuing hyperpietic; 5, arrhythmia, tetrodotoxin, TTX have obvious antiarrhythmic activity, if with other antiarrhythmic drug adapteds, can significantly strengthen ARR curative effect; 6, treating narcotic addiction, injects after micro-Fugu ocellatus toxin junkie, and all various " treating narcotic addiction syndromes " all disappeared after 30 minutes, injects continuously after 5 days treating narcotic addiction completely.Within 1998, Canadian international Wei Kesi technology company utilizes Fugu ocellatus toxin successfully to develop the treating drug-addict of a kind of " tetrodin " by name.In addition, Fugu ocellatus toxin has also been obtained remarkable effect at aspects such as treatment enuresis, impotence, female libido disappearance, slow down aging, raising immunity.Thereby Fugu ocellatus toxin has very large medicinal exploitation value.
The production method of Fugu ocellatus toxin mainly contains chemical synthesis, biological tissue extracted method, microbe fermentation method.Wherein chemical synthesis complex steps, yield is low, product purity is not high; Tissue extraction method need consume a large amount of globe fish resources, destroys ecosystem; Microbe fermentation method exists toxigenic bacterium strain inherited character unstable, needs bacterial exotoxin is separated from mixture through special isolation technics means purifying technique complexity, the defect such as yield rate is little, antibacterial quality is lower.Therefore, be necessary to study a kind of brand-new Fugu ocellatus toxin production method.ZL200910075184.7 and ZL200920104149.9 have announced a kind of bacterial exotoxin Dialysis culture method and corresponding microbial dialysis incubator, produce new approaches are provided for Fugu ocellatus toxin.
At present, Fugu ocellatus toxin pharmaceutical carrier is in the majority with the injection of solution form, but the safety of Fugu ocellatus toxin injection is low, once accidentally flow into society, is very easily utilized and carries out illegal activity by lawless person.In addition, when the injection of Fugu ocellatus toxin injection, can bring certain misery, also not be suitable for external.In the patent of publication number CN101066340A, a kind of compound externally applied tetrodotoxin ointment and preparation method thereof is disclosed, take Oleum Fugu ocellatus as active component, make a kind of externally used coating ointment, in order to tackle the symptoms such as wound (comprising I, II degree burn), trauma infection contamination, but there are no the report that adopts Fugu ocellatus toxin as pad pasting medicament.
Botulinum toxin is as the existing applicating history for many years of main medicine of beauty treatment reduce wrinkle, but botulinum toxin now mainly adopts injection system, exists certain painfully, and needs to special beauty treatment mechanism, could implement by professional.
Summary of the invention
The technical issues that need to address of the present invention be to provide a kind ofly itch by sticking that just can having disappears, the pad pasting of pain relieving, the effect of beauty treatment reduce wrinkle.
For solving the problems of the technologies described above, the technical solution used in the present invention is: a kind of Fugu ocellatus toxin pad pasting, comprise and be arranged in epilamellar medicine, described medicine comprises medicinal active ingredient Fugu ocellatus toxin and stabilizing agent lactose, cosolvent citric acid, zinc oxide, Colophonium, vaseline, Herba Menthae quintessence oil.
Further improvement of the present invention is: in described Fugu ocellatus toxin pad pasting, each components in mass portion number is counted: 1 ~ 9 part of Fugu ocellatus toxin, 3.5 ~ 1500 parts of lactose, 1 ~ 200 part of citric acid, 30 ~ 500 parts of zinc oxide, 60 ~ 2000 parts of Colophonium, 1000 ~ 8000 parts, vaseline, 80 ~ 600 parts of Herba Menthae quintessence oils.
Further improvement of the present invention is: in described Fugu ocellatus toxin pad pasting, the mass fraction of Fugu ocellatus toxin is 1 ~ 3 part.
Further improvement of the present invention is: in described Fugu ocellatus toxin pad pasting, the mass fraction of Fugu ocellatus toxin is 3 ~ 5 parts.
Further improvement of the present invention is: in described Fugu ocellatus toxin pad pasting, the mass fraction of Fugu ocellatus toxin is 6 ~ 9 parts.
A preparation method for Fugu ocellatus toxin pad pasting, comprises the following steps:
A, Fugu ocellatus toxin extract:
Collect Fugu ocellatus toxin Dialysis culture bacterium liquid, then centrifugal treating under the environment of 0 ℃, gets supernatant, mixes with picric acid in the ratio of 1.0:1～1.2:1, and gained mixed liquor mixes with boiling water in the ratio of 1:5～1:7, filtered while hot; Cooling filtrate, obtains crystalline deposit, fractional crystallization precipitation, and this is deposited in boiling water to recrystallization three times, obtain yellow needle-like Fugu ocellatus toxin picrate crystal salt; Fugu ocellatus toxin picrate is dissolved in boiling water, and the pH value of gained Fugu ocellatus toxin picrate solution is adjusted to 9 with ammonia, after cooling Fugu ocellatus toxin crystal; Gained Fugu ocellatus toxin crystal is dissolved with spirit of vinegar, and regulate pH value to 9 with ammonia again, and then crystallization purifying, and the required Fugu ocellatus toxin that after gained crystal is dry is;
B, by Fugu ocellatus toxin porphyrize, in proportion with citric acid mixed dissolution, add in proportion lactose, uniform stirring simultaneously;
C, the Fugu ocellatus toxin having dissolved is evenly mixed in proportion with zinc oxide, Colophonium, vaseline, Herba Menthae quintessence oil, make patch.
Owing to having adopted technique scheme, the obtained technological progress of the present invention is: Fugu ocellatus toxin is made to a kind of externally used pad pasting, change the route of administration of traditional Fugu ocellatus toxin medicament, directly carry out topical from human external, Fugu ocellatus toxin will no longer enter organism blood circulation, and directly acting on skin and subcutaneous shallow-layer muscle nerve, onset is rapider, uses convenient, easy.Meanwhile, Fugu ocellatus toxin pad pasting make Fugu ocellatus toxin medicament preservation, use convenient, safety, and greatly alleviated patient because using Fugu ocellatus toxin injection to inject the pain of bringing.In addition, the relatively existing Fugu ocellatus toxin externally-used pain-relieving of Fugu ocellatus toxin pad pasting ointment, can make medicine and the external world isolate completely, can set-off clothes, and patient uses health, convenience more.
Fugu ocellatus toxin pad pasting is according to the difference of Determination of Tetrodotoxin, can play respectively the effect of antipruritic, analgesia or beauty treatment reduce wrinkle, when the mass fraction of Fugu ocellatus toxin is 1 ~ 3 part in pad pasting, mainly can play itching-relieving action, its analgesic effect and beauty treatment wrinkle improvement effect slightly a little less than; When the mass fraction of Fugu ocellatus toxin is 3 ~ 5 parts in pad pasting, be mainly used in pain relieving, but also can play effect antipruritic and beauty treatment reduce wrinkle; When the mass fraction of Fugu ocellatus toxin is 6 ~ 9 parts in pad pasting, in thering is cosmetic result, also there is analgesia, antipruritic effect.Effect that Fugu ocellatus toxin and botulinum toxin all have paralysis teleneuron, smooth away wrinkles, the appearance of Fugu ocellatus toxin pad pasting, the normalization of beauty treatment reduce wrinkle will be contributed to realize, consumer can implement beauty treatment reduce wrinkle by pad pasting voluntarily, help medical and beauty treatment mechanism without relending, and eliminated the pain of bringing while injecting botulinum toxin.
In Fugu ocellatus toxin pad pasting of the present invention, in Fugu ocellatus toxin effluent tetrodotoxin Dialysis culture liquid used, extract, Fugu ocellatus toxin Dialysis culture method can make every ml culture fluid produce poison amount and be increased to mg level from ng level, product poison has measured and has increased substantially, and has greatly reduced Fugu ocellatus toxin production cost.Meanwhile, Fugu ocellatus toxin pad pasting institute using dosage is only the one thousandth of minimum lethal dose, has greatly improved the safety of Fugu ocellatus toxin medicament.Also slackened to a certain extent because of the Fugu ocellatus toxin medicament social safety hidden danger causing that runs off simultaneously.
Actual experiment research is found, Fugu ocellatus toxin pad pasting of the present invention onset time compared with other medicines with analgesia, antipruritic effect shortens greatly, and the shortest 10 ~ 30min gets final product onset, and drug effect is more lasting, sustainable 48 ~ 72h, uses 3 days pain to be eliminated continuously.Fugu ocellatus toxin pad pasting wrinkle improvement effect of the present invention can reach 120 ~ 150h.500 of 1000 of Fugu ocellatus toxin pad pastings that utilize the present invention to manufacture experimently 6cm × 10cm to there is analgesic activity, the Fugu ocellatus toxin pad pastings with itching-relieving action, the pad pasting 500 with beauty treatment wrinkle improvement effect pastes, effective percentage 100% on probation, drug effect is described above, and after using there are no any toxic and side effects.
The specific embodiment
Below in conjunction with embodiment, the present invention is explained in further detail to (following medicine according to the mass fraction).
Medicine in embodiment 1 ~ 5 is evenly coated on hospital gauze or makes patch, medicine thickness is as the criterion can cover gauze, can be for antipruritic and analgesia; Medicine in embodiment 7 ~ 9 is evenly coated on face paper or makes pad pasting, can be for beauty treatment reduce wrinkle.
Preparation process is:
A, Fugu ocellatus toxin extract:
Collect Fugu ocellatus toxin Dialysis culture bacterium liquid, then centrifugal treating under the environment of 0 ℃, gets supernatant, mixes with picric acid in the ratio of 1.1:1, and gained mixed liquor mixes with boiling water in the ratio of 1:6, filtered while hot;
Cooling filtrate, obtains crystalline deposit, fractional crystallization precipitation, and this is deposited in boiling water to recrystallization three times, obtain yellow needle-like Fugu ocellatus toxin picrate crystal salt;
Fugu ocellatus toxin picrate is dissolved in boiling water, and gained Fugu ocellatus toxin picrate pH is adjusted to 9 with ammonia, after cooling Fugu ocellatus toxin crystal;
Gained Fugu ocellatus toxin crystal is dissolved with spirit of vinegar, and regulate pH value to 9 with ammonia again, and then crystallization purifying, and the required Fugu ocellatus toxin that after gained crystal is dry is;
B, by Fugu ocellatus toxin porphyrize, according to above-mentioned mass fraction and citric acid mixed dissolution, add the lactose of above-mentioned mass fraction, uniform stirring simultaneously;
C, the Fugu ocellatus toxin having dissolved is evenly mixed according to portion rate with zinc oxide, Colophonium, vaseline, Herba Menthae quintessence oil, make patch.
Mrs Feng of in JIUYUE, 2011 Shijiazhuang City itches because shank is dry, need constantly scratch, and once smears multiple itching-relieving cream, DeGrain.JIUYUE 22 days, sticks the antipruritic plaster in the present embodiment 1 in affected part, no longer exists dry gargalesthesia and feel after 20 minutes, and this plaster is sticked to 30 hours always, then changes another note, makes plaster stick two days in affected part, naturally comes off, and after this no longer itch in this patient's affected part.
In October, 2011, Mr. Li of Shijiazhuang City itched because allergy occurs that arm is dry, once took multiple Claritin, DeGrain.October 3, sticks the antipruritic plaster in the present embodiment 2 in affected part, no longer exists dry gargalesthesia and feel after 15 minutes, and this plaster is sticked to 24 hours always, then changes another note, makes plaster stick continuously three days in affected part, naturally comes off afterwards, and dry itching eliminated completely.
In August, 2011 Shijiazhuang City dry the itching in poplar back, constantly after scratching, scratch hemorrhage, itch pain unbearably, with sticking in affected part by the antipruritic plaster in the present embodiment 3, after 30 minutes, dry itching is all eliminated with pain, this plaster being sticked to 30 hours always, it is come off naturally, itches to keenly feel and does not recur again in this patient affected part.
Mr. Zhao of in JIUYUE, 2011 Shijiazhuang City scratches massive hemorrhage because traffic accident causes ancon, hurt like hell, and oral relieving the pain after tablet, loses effect.JIUYUE 15 days, sticks the analgesia plaster in the present embodiment 4 in affected part, and after 30 minutes, pain is greatly alleviated, and this plaster was sticked after 48 hours, changes another note, sticks continuously after 3 days, and pain is eliminated.
In October, 2011, Shijiazhuang City Lee carried out caesarean operation, the postoperative analgesia plaster sticking on the edge of a knife in the present embodiment 5, after 25 minutes, pain is greatly alleviated, this plaster is sticked to 48 hours continuously, change another note, stick continuously after 7 days, pain is eliminated, and edge of a knife vestige is also alleviated.
In JIUYUE, 2012 Shijiazhuang City Mrs Wang uses the beauty mask in the present embodiment 6 to carry out beautifying face reduce wrinkle, takes off pad pasting after sticking 20 minutes, and facial wrinkles is effectively desalinated, and this effect can keep 140h, and any untoward reaction does not appear in the trial employment period.
In October, 2012, Shijiazhuang City granddaughter scholar used the beauty mask in the present embodiment 7 to carry out beautifying face reduce wrinkle, took off pad pasting after sticking 18 minutes, and facial wrinkles is effectively desalinated, and this effect can keep 135h, and any untoward reaction does not appear in the trial employment period.
In October, 2011, Mrs Qian of Shijiazhuang City used the beauty mask in the present embodiment 8 to carry out beautifying face reduce wrinkle, took off pad pasting after sticking 15 minutes, found facial wrinkles desalination, and this effect persistent period be 130h, there is not any untoward reaction in the trial employment period.
In November, 2011, Shijiazhuang City Mrs Zhao used the beauty mask in the present embodiment 9 to carry out beautifying face reduce wrinkle, took off pad pasting after sticking 20 minutes, found that facial wrinkles is effectively desalinated, and this effect can keep 150h, and any untoward reaction does not appear in the trial employment period.
Claims (4)
1. a Fugu ocellatus toxin pad pasting, comprises and is arranged in epilamellar medicine, it is characterized in that: described medicine comprises medicinal active ingredient Fugu ocellatus toxin and stabilizing agent lactose, cosolvent citric acid, zinc oxide, Colophonium, vaseline, Herba Menthae quintessence oil; In described Fugu ocellatus toxin pad pasting, the mass fraction of each component is counted: 1～9 part of Fugu ocellatus toxin, 3.5～1500 parts of lactose, 1～200 part of citric acid, 30～500 parts of zinc oxide, 60～2000 parts of Colophonium, 1000～8000 parts, vaseline, 80～600 parts of Herba Menthae quintessence oils;
The preparation method of Fugu ocellatus toxin pad pasting comprises the following steps
A, Fugu ocellatus toxin extract:
Collect Fugu ocellatus toxin Dialysis culture bacterium liquid, then centrifugal treating under the environment of 0 ℃, gets supernatant, mixes with picric acid in the ratio of 1.0:1～1.2:1, and gained mixed liquor mixes with boiling water in the ratio of 1:5～1:7, filtered while hot;
Cooling filtrate, obtains crystalline deposit, fractional crystallization precipitation, and this is deposited in boiling water to recrystallization three times, obtain yellow needle-like Fugu ocellatus toxin picrate crystal salt;
Fugu ocellatus toxin picrate is dissolved in boiling water, and the pH value of gained Fugu ocellatus toxin picrate solution is adjusted to 9 with ammonia, after cooling Fugu ocellatus toxin crystal;
Gained Fugu ocellatus toxin crystal is dissolved with spirit of vinegar, and regulate pH value to 9 with ammonia again, and then crystallization purifying, and obtain required Fugu ocellatus toxin after gained crystal is dry;
B, by Fugu ocellatus toxin porphyrize, in proportion with citric acid mixed dissolution, add in proportion lactose, uniform stirring simultaneously;
C, the Fugu ocellatus toxin having dissolved is evenly mixed in proportion with zinc oxide, Colophonium, vaseline, Herba Menthae quintessence oil, make patch.
2. Fugu ocellatus toxin pad pasting according to claim 1, the mass fraction that it is characterized in that Fugu ocellatus toxin in described Fugu ocellatus toxin pad pasting is 1～3 part.
3. Fugu ocellatus toxin pad pasting according to claim 1, the mass fraction that it is characterized in that Fugu ocellatus toxin in described Fugu ocellatus toxin pad pasting is 3～5 parts.
4. Fugu ocellatus toxin pad pasting according to claim 1, the mass fraction that it is characterized in that Fugu ocellatus toxin in described Fugu ocellatus toxin pad pasting is 6～9 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210459177.9A CN102920684B (en) | 2012-11-15 | 2012-11-15 | Tetradotoxin mask and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210459177.9A CN102920684B (en) | 2012-11-15 | 2012-11-15 | Tetradotoxin mask and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102920684A CN102920684A (en) | 2013-02-13 |
| CN102920684B true CN102920684B (en) | 2014-05-28 |
Family
ID=47635712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210459177.9A Active CN102920684B (en) | 2012-11-15 | 2012-11-15 | Tetradotoxin mask and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102920684B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101066340A (en) * | 2007-05-16 | 2007-11-07 | 苏振芳 | Compound externally applied tetrodotoxin ointment and its prepn |
| CN101264063A (en) * | 2007-03-15 | 2008-09-17 | 深圳市宏锦天生物科技有限公司 | Stable tetrodotoxin preparations under room temperature for injection |
-
2012
- 2012-11-15 CN CN201210459177.9A patent/CN102920684B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264063A (en) * | 2007-03-15 | 2008-09-17 | 深圳市宏锦天生物科技有限公司 | Stable tetrodotoxin preparations under room temperature for injection |
| CN101066340A (en) * | 2007-05-16 | 2007-11-07 | 苏振芳 | Compound externally applied tetrodotoxin ointment and its prepn |
Non-Patent Citations (3)
| Title |
|---|
| 许实波等.河豚毒素.《海洋生物制药》.化学工业出版社,2007,第355页. * |
| 马玉凤等.鱼肝油药膏治疗肛周皮肤溃疡.《中华护理杂志》.2006,第20卷(第11期),第2988页. |
| 鱼肝油药膏治疗肛周皮肤溃疡;马玉凤等;《中华护理杂志》;20061130;第20卷(第11期);第2988页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102920684A (en) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101508614B1 (en) | Anti-aging cosmetic composition comprising the poison complex of spider silk protein, leech extracts, bee venom extracts and snake venom peptide | |
| JPH06500708A (en) | Improved iontophoretic administration of drugs | |
| CN1762967B (en) | Enoxolone derivative, preparation method and uses | |
| CN105582383A (en) | Composition containing alkannin and lemon grass essential oil | |
| CN112587593A (en) | Composition for treating acne and preparation method thereof | |
| KR102623984B1 (en) | Cannabinoid compositions and their use in the manufacture of drugs for treating neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. | |
| CN103202786B (en) | Traditional Chinese medicine composition extract with anti-dandruff function and application of same in cosmetic | |
| JP2024055895A (en) | Methods of treating basal cell carcinoma and glioblastoma | |
| CN101332302B (en) | Formula for preparing anti-eczema and cutitis products and preparation method thereof | |
| CN102872158B (en) | External drug combination for curing eczema and preparation method thereof | |
| CN105168361A (en) | Compound plant oil liniment for treating burns and scalds and preparation method of compound plant oil liniment | |
| CN102335231B (en) | Chinese medicinal moisturizing cream for treating chloasma as well as preparation method and application thereof | |
| CN101584715B (en) | Spray for preventing and treating skin damnification and resisting infection | |
| CN102920684B (en) | Tetradotoxin mask and preparation method thereof | |
| CN103432049B (en) | Composition with deodorization function | |
| CN103006681B (en) | Compound emulsifiable paste for treating acne and preparation method thereof | |
| CN101897693B (en) | Catechin compounds or application of plant extraction containing same and pharmaceutical composition | |
| CN104083406B (en) | A kind of compound disinfectant and preparation method thereof | |
| US10369170B1 (en) | Methods of treating basal cell carcinoma and glioblastoma | |
| CN104510752A (en) | Medical application of astrapterocarpan | |
| CN114272290B (en) | A topical compound Chinese medicinal extract for treating cancer pain of all steps, and its preparation method | |
| CN102302636A (en) | Medicament for treating burn and preparation method thereof | |
| CN102727537A (en) | Tinea-sore-removing ointment | |
| KR101505903B1 (en) | Composition containing Euphorbia kansui extract, fractions thereof or diterpene compound isolated from the fraction for wound-healing or skin activation | |
| CN1097601A (en) | The medicine and the preparation technology thereof of treatment tinea pedis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200518 Address after: 050000 office building 516, waste cotton dormitory, No.20 Huaibei Road, Qiaoxi District, Shijiazhuang City, Hebei Province Patentee after: Hebei Steiner Biotechnology Co., Ltd Address before: 1-142 room 12, No. 810000, Jiefang Road, Xining, Qinghai Patentee before: Lin Tao |
|
| TR01 | Transfer of patent right |